Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06526793 · ClinicalTrials.gov registry record · Phase 2
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
A Phase 2 study of B-Cell Non-Hodgkin Lymphoma and Follicular Lymphoma (FL), sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
- 20
- Study locations
NCT06526793: Recruiting Phase 2 study of B-Cell Non-Hodgkin Lymphoma and Follicular Lymphoma (FL), sponsored by AstraZeneca.
NCT06526793 is a Phase 2 study of B-Cell Non-Hodgkin Lymphoma and Follicular Lymphoma (FL) that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 240 participants, above the 120-participant average among 24 other B-Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (100% higher). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06526793, a Phase 2 study of B-Cell Non-Hodgkin Lymphoma and Follicular Lymphoma (FL), is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of Surovatamig (AZD0486) monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least two prior lines of therapies. The study has 2 Modules: Module 1 for FL and Module 2 for LBCL.
Primary Outcome
Overall response summarized via overall response rate (ORR), defined as the proportion of participants achieving either a Partial Response (PR) or Complete Response (CR) based on Lugano 2014 response criteria for non-Hodgkin Lymphoma, as determined by central review
Conditions Studied
Interventions
- DRUG Surovatamig
Study Locations (20)
Pennsylvania
- Research Site - Philadelphia
- Research Site - Pittsburgh
- Research Site - Pittsburgh
Florida
- Research Site - Jacksonville
- Research Site - Tampa
Iowa
- Research Site - Iowa City
- Research Site - Waukee
Arizona
- Research Site - Phoenix
California
- Research Site - Duarte
Illinois
- Research Site - Chicago
Kansas
- Research Site - Overland Park
Minnesota
- Research Site - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2024-11-27 |
| Est. Completion | 2029-06-14 |
| Phase | Phase 2 |
What NCT06526793 shows while recruiting
NCT06526793 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, above the 120-participant average among 24 other B-Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (100% higher).
The record links to 3 conditions, with B-Cell Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Surovatamig is the first listed.
NCT06526793 names 20 study sites across 16 states, led by Pennsylvania, Florida, Iowa.
Frequently Asked Questions
What is clinical trial NCT06526793 about?
NCT06526793 is a clinical study titled "Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL". This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of Surovatamig (AZD0486) monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least two prior lines of therapies. The study has 2 Modu...
What is the current status of trial NCT06526793?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2024-11-27. Estimated completion is 2029-06-14.
What conditions does trial NCT06526793 study?
This clinical trial studies the following conditions: B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL).
What interventions are being tested in trial NCT06526793?
The interventions under investigation include: Surovatamig (DRUG).
Who is sponsoring clinical trial NCT06526793?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06526793 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for B-Cell Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06526793's enrollment target sits among peer trials
240 5th of 24 higher than 20 of 24 other B-Cell Non-Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other B-Cell Non-Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
RECRUITING · Phase 2
-
Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
RECRUITING · Phase 2
-
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
RECRUITING · Phase 2
-
Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy
ACTIVE NOT RECRUITING · Phase 2
-
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI